Confesercenti Partner
Related Articles
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company specializing in therapies for tumor recurrence and hard-to-treat established tumors, today announced participation in the following conferences:
Red eye growth day 2022
June 2, 2022
Immunicum CEO Erik Manting will participate in an on-site Q&A session on June 2 at 08:55 CET. Further details, including the on-demand corporate presentation, are available via:
https://redeye.ifairs.com/#/booth?id=687
BioStock Life Sciences Spring Summit
June 8-9, 2022
Immunicum CEO Erik Manting will present on June 9 at 10:20 a.m. CET.
European Hematology Association (EHA) Congress 2022
June 9-17, 2022
https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/
Organic International Convention
June 13-16, 2022
https://www.bio.org/events/bio-international-convention
FOR MORE INFORMATION PLEASE CONTACT:
Erik Manting
Chief executive officer
Email: [email protected]
INVESTOR RELATIONS
Julie Seidel
Serious investor relations
Telephone: +1 212-362-1200
Email: [email protected]
MEDIA RELATIONS
Mario Brkulj
Valencia Communications
Telephone: +49 160 9352 9951
Email: [email protected]
ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company specializing in therapies for tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We leverage our unrivaled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel off-the-shelf cell therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is listed on Nasdaq Stockholm. www.immunicum.com
-
220601_Immunicum_Conferences_June_ENG
